Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online September 1, 2022.
Article Versions
- Latest version (September 1, 2022 - 04:00).
- You are currently viewing a Latest version of this article (September 1, 2022 - 08:00).
- latest version (November 1, 2022 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2022 The Journal of Rheumatology
Author Information
- Bernice L. Sim,
- Beatrice Z. Sim,
- Matthew Tunbridge,
- David F.L. Liew and
- Philip C. Robinson
-
PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB and grant funding from Janssen, Novartis, Pfizer and UCB Pharma.
St. George's Hospital Medical School, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom; Faculty of Medicine, The University of Queensland, Herston, QLD, Australia; Department of Rheumatology and Department of Clinical Pharmacology and Therapeutics, Austin Health, 145 Studley Rd, Heidelberg VIC 3084, Australia; Department of Medicine, University of Melbourne, Parkville, VIC, Australia; Department of Rheumatology, Royal Brisbane & Women's Hospital, Metro North Hospital and Health Service, Herston, Queensland, Australia.
Corresponding Author: Associate Professor Philip Robinson, University of Queensland School of Clinical Medicine, Royal Brisbane & Women's Hospital, Herston, Queensland 4006, Australia.